BiPar Sciences

BiPar Sciences is a privately held biotechnology company located in South San Francisco, California. The company employs 8 people and generates over $10,000 in annual revenue. BiPar Sciences is dedicated to developing innovative cancer therapies. The company's primary focus is on PARP inhibitors, a novel class of drugs designed to target multiple cancer types, including those resistant to conventional treatments. Their lead product candidate, iniparib, inhibits PARP1, an enzyme crucial for DNA repair and cell growth. Iniparib has demonstrated the ability to significantly enhance the effectiveness of chemotherapy and has shown promising safety and efficacy in clinical trials for solid tumors. BiPar Sciences is currently conducting Phase 2 and Phase 3 clinical trials evaluating iniparib in advanced solid tumors, including triple-negative breast cancer. In addition to iniparib, the company is developing two other compounds: BSI-401, a follow-on PARP inhibitor for oral treatment of pancreatic cancer, and BSI-302, a novel anti-tubulin therapy. For more information about BiPar Sciences and its research, please visit their website at bipasciences.com.